


What Is the Prognostic Significance of Anti-Ro52 Positivity in Patients With Interstitial Lung Disease (ILD)?


STUDY DESIGN

- Retrospective cohort study




RESULTS

ILD Progression-Free Survival



Lung Transplant-Free Survival



After a median follow-up of 25.6 months, participants with anti-Ro52+ ILD had:

- **HR, 2.10 (95% CI, 1.61-2.73)** for ILD progression or death
- **HR, 1.61 (95% CI, 1.11-2.35)** for lung transplant or death

Our results indicate that anti-Ro52 positive ILD is associated with significantly worse progression-free and transplant-free survival and may inform disease prognostication and monitoring.